Alpha-glucosidase inhibitors

Endocrinology and Metabolism Clinics of North America

Volumn 26, Issue 3, 1997, Pages 539-551

  Lebovitz, H E ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETIC ACID; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; AMYLASE; ANTIDIABETIC AGENT; BETA GLUCOSIDASE; CARBOHYDRATE; CARBON DIOXIDE; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSE; HEMOGLOBIN A1C; HYDROGEN; INSULIN; LACTASE; METFORMIN; MIGLITOL; MONOSACCHARIDE; OLIGO 1,6 GLUCOSIDASE; OLIGOSACCHARIDE; SHORT CHAIN FATTY ACID; STARCH; SUCRASE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; UNINDEXED DRUG; VOGLIBOSE;

CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DIET THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; POSTPRANDIAL STATE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

EID: 0030755109     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70266-8     Document Type: Article

References (53)

1. M. Bayraktar N. Adalar D.H. Van Thiel A comparison of acarbose versus metformin as an adjunct therapy in sulfonylurea-treated NIDDM patients Diabetes Care 19 1996 252
2. D. Braun U. Schonherr H.-J. Mitzkat Efficacy of acarbose monotherapy in patients with type 2 diabetes: A double-blind study conducted in general practice Endocrinol Metab 3 1996 275
3. A. Ceriello C. Taboga L. Tonutti Post-meal coagulation activation in diabetes mellitus: The effect of acarbose Diabetologia 39 1996 469
4. J.-L. Chiasson R.G. Josse J.A. Hunt The efficacy of acarbose in the treatment of patients with non–insulin-dependent diabetes mellitus Ann Intern Med 121 1994 928
5. J.-L. Chaisson D.M. Nathan R.G. Josse The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance Diabetes Care 19 1996 1190
6. R.F. Coniff B.J. Hoogwerf J.A. Shapiro A double-blind controlled trial evaluating the safety and efficacy of acarbose for treatment of patients with insulin requiring type II diabetes Diabetes Care 18 1995 928
7. R.F. Coniff T.B. Seaton J.A. Shapiro Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM Diabetes Care 18 1995 817
8. R.F. Coniff J.A. Shapiro T.B. Seaton Long-term efficacy and safety of acarbose in the treatment of obese subjects with non–insulin-dependent diabetes mellitus Arch Intern Med 154 1994 2442
9. R.F. Coniff J.A. Shapiro T.B. Seaton Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non–insulin-dependent diabetes mellitus Am J Med 98 1995 443
10. M. De Vecinia Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy N Engl J Med 33 1995 1239
11. G. Dimitriadis K. Karaiskos S. Raptis Effects of prolonged (6 months) alpha glucosidase inhibition on blood glucose control and insulin requirement in patients with insulin dependent diabetes mellitus Horm Metab Res 18 1986 253
12. R.P. Donahue R.D. Abbott D.M. Reed Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program Diabetes 36 1987 689
13. J.W. Ensink D.A. D'Alessio The enteroinsular axis revisited: A novel role for incretin N Engl J Med 326 1992 1352
14. J. Gerard A.S. Luyckx P. Lefebvre Acarbose in reactive hyperglycemia: A double blind study Int J Clin Pharmacol Ther Toxicol 22 1984 25
15. B. Goke C. Herrmann R. Goke Intestinal effects of x glucosidase inhibitors: Absorption of nutrients and enterohormonal changes Eur J Clin Invest 24 suppl 3 1994 25
16. M. Greenfield O. Kolterman J.M. Olefsky The effect of ten days of fasting on various aspects of carbohydrate metabolism in obese subjects with significant fasting hyperglycemia Metabolism 27 suppl 2 1978 1839
17. J.F. Habner The incretin notion and its relevance to diabetes Endocrinol Metab Clin North Am 22 1993 775
18. M. Hanefeld S. Fischer J. Schulze Therapeutic potential of acarbose as first line drug in non–insulin-dependent diabetes insufficiently treated with diet alone Diabetes Care 14 1991 732
19. T. Hara F. Sakakibara J. Nakamura An importance of carbohydrate ingestion for the expression of the effect of alpha glucosidase inhibitor in NIDDM Diabetes Care 19 1996 642
20. M.I. Harris Undiagnosed NIDDM: Clinical and public health issues Diabetes Care 16 1993 642
21. Harris MI: Classification, diagnostic criteria and screening for diabetes. In Diabetes in America, ed 2. Bethesda, MD, (NIH Publication No. 95-1468), 1995, p 15
22. M.I. Harris R. Klein T.A. Welborn Onset of NIDDM occurs at least 4–7 yrs before clinical diagnosis Diabetes Care 15 1992 815
23. M. Hiele Y. Ghoos R. Rutgeerts Effects of acarbose on starch hydrolysis: Study in healthy subjects, ileostomy patients and in vitro Dig Dis Sci 37 1992 1057
24. J. Hoffman M. Spengler Efficacy of 24 week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients: The essen study Diabetes Care 17 1994 561
25. J. Hoffman M. Spengler Efficacy of 24 week monotherapy with acarbose, metformin or placebo in NIDDM patients with dietary failure Diabetologia 39 suppl 1 1996 873
26. P.A. Hollander Acarbose: Adverse events and safety profile Drug Benefit Trends 8 suppl E 1996 46
27. P. Hollander X. Pi-Sunyer R.F. Coniff Acarbose in the treatment of type 1 diabetes Diabetes Care 20 1997 248
28. R.R. Holman C.A. Cull R.C. Turner Glycemic improvement over one-year in a double blind trial of acarbose in 1946 NIDDM patients Diabetologia 39 suppl 1996 156
29. J. Holst GLP-1 in NIDDM Diabetic Med 13 1996 5156
30. P.R. Holt E. Atillasoy J. Lindenbaum Effects of acarbose on fecal nutrients, colonic PH, and short chain fatty acids and rectal proliferative indices Metabolism 45 1996 1179
31. N. Hotta H. Kakuta T. Sano Long-term effect of acarbose on glycaemic control in non–insulin-dependent diabetes mellitus: A placebo-controlled double-blind study Diabetic Med 10 1993 134
32. R.J. Jarrett H. Keen P. McCartney The Whitehall study: Ten year follow-up on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death Diabetic Med 1 1984 279
33. A. Jenney A. Nankervis J. Proietto Low dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity Diabetes Care 16 1993 499
34. A.B. Johnson R. Taylor Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients? Diabetes Care 19 1996 559
35. Johnston R, Lebovitz HE: Advantages of monotherapy with alpha-glucosidase inhibitors in elderly NIDDM patients. Abstract presented at the American Diabetes Association Annual Meeting, Boston, 1997
36. P.S. Johnston J.V. Santiago R.F. Coniff Effects of the carbohydrate inhibitor miglitol in sulfonylurea-treated NIDDM patients Diabetes Care 17 1994 20
37. B. Junge M. Matzke J. Stoltefuss Chemistry and structure-activity relationships of glucosidase inhibitors J. Kuhlman W. Puls Oral Antidiabetics 1996 Springer-Verlag Berlin 411
38. J. Kobberling Nonpharmacological management of non–insulin-dependent diabetes J. Kuhlmann W. Puls Oral Antidiabetics 1996 Springer-Verlag Berlin 43
39. H.P. Krause H.J. Ahr Pharmacokinetics and metabolism of glucosidase inhibitors J. Kuhlmann W. Puls Oral Antidiabetics 1996 Springer-Verlag Berlin 541
40. W. Leonhardt M. Hanefeld S. Fischer Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia Eur J Clin Invest 24 suppl 3 1994 5
41. J. Lindstrom J. Tuomilehto M. Spengler The effect of acarbose on dietary nutrient intake and metabolic control in NIDDM patients Diabetologia 39 suppl 1 1996 739
42. C. May Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non–insulin-dependent diabetes (NIDDM), treated with sulphonylureas Diabetes Stoffwechsel 4 1995 3
43. D.K. McCulloch A.B. Kurtz R.B. Tattersall A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition Diabetes Care 6 1983 483
44. K. O'Dea Marked improvement in carbohydrate and lipid metabolism in diabetic Australian aborigines after temporary reversion to traditional lifestyle Diabetes 33 1984 596
45. W. Puls Pharmacology of glucosidase inhibitors J. Kuhlman W. Puls Oral Antidiabetics 1996 Springer-Verlag Berlin 497
46. C. Qualmann M.A. Nauck J.J. Holst Glucagon-like peptide 1 (GLP1) secretion in response to luminal sucrose from the upper and lower gut: A study using alpha-glucosidase inhibition (Acarbose) Scand J Gastroenterol 30 1995 892
47. F. Requejo L.O. Uttenthal S.R. Bleom Effects of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses Diabetic Med 7 1990 515
48. C. Rosak G. Nitzsche P. Konig The effect of the timing and the administration of acarbose on postprandial hyperglycemia Diabetic Med 12 1995 979
49. F. Santeusanio M.M. Ventura S. Contadini Efficacy and safety of 2 different dosages of acarbose in non–insulin-dependent diabetic patients treated by diet alone Diabetes Nutr Metab Clin Exp 6 1993 147
50. E. Standl New drugs for diabetes S.M. Marshall P.D. Home R.A. Rizza The Diabetes Annual/10 1996 Elsevier Amsterdam 228
51. R. Tattersall Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes Diabetic Med 10 1993 688
52. J. Wing W.J. Kalk M. Berzin The acute effects of glucosidase inhibition on post-meal glucose increments in insulin-dependent diabetics South Afr Med J 77 1990 286
53. T.M.S. Wolever R. Radmard J.-L. Chiasson One-year acarbose treatment raises fasting serum acetate in diabetic patients Diabetic Med 12 1995 164